Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy

Urology

Volumn 76, Issue 2, 2010, Pages 512.e1-512.e7

  Seo, Ho Kyung ^a   Cho, Kang Su ^a   Chung, Jinsoo ^a   Joung, Jae Young ^a   Park, Weon Seo ^a   Chung, Moon Kee ^a   Lee, Kang Hyun ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MITOMYCIN C; PROTEIN P53;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUSCLE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION;

EID: 77955717288     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.04.040     Document Type: Article

References (28)

1. F. Millan-Rodriguez, G. Chechile-Toniolo, and J. Salvador-Bayarri Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 164 2000 680 684
2. A. Horvath, and H. Mostafid Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer BJU Int 103 2009 726 729
3. T. Habuchi, M. Marberger, and M.J. Droller Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers Urology 66 2005 64 74 (Pubitemid 43049609)
4. C. Cordon-Cardo, Z.F. Zhang, and G. Dalbagni Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors Cancer Res 57 1997 1217 1221
5. J. Serth, M.A. Kuczyk, and C. Bokemeyer p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder Br J Cancer 71 1995 201 205
6. L. Lacombe, G. Dalbagni, and Z.F. Zhang Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Gurin therapy: correlation to clinical outcome J Clin Oncol 14 1996 2646 2652
7. C. Pfister, L. Moore, and P. Allard Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence Clin Cancer Res 5 1999 4079 4084
8. A. Pich, L. Chiusa, and A. Formiconi Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder Cancer 95 2002 784 790
9. I. Frank, J.C. Cheville, and M.L. Blute Prognostic value of p53 and MIB-1 in transitional cell carcinoma of the urinary bladder with regional lymph node involvement Cancer 101 2004 1803 1808
10. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
11. M.D. Shelley, T.J. Wilt, and J. Court Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials BJU Int 93 2004 485 490
12. A. Bohle, D. Jocham, and P.R. Bock Intravesical bacillus Calmette-Gurin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 2003 90 95
13. M. Huncharek, and B. Kupelnick Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation Am J Clin Oncol 26 2003 402 407
14. P.U. Malmstrm, R.J. Sylvester, and D.E. Crawford An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gurin for non-muscle-invasive bladder cancer Eur Urol 56 2009 247 256
15. G. Dalbagni Is intravesical bacillus Calmette-Gurin better than mitomycin for intermediate-risk bladder cancer? Eur Urol 56 2009 257 259
16. A.W. Hitchings, M. Kumar, and S. Jordan Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb Br J Cancer 91 2004 552 557
17. S.F. Shariat, J. Kim, and G. Raptidis Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder Urology 61 2003 1140 1145
18. T. Liukkonen, P. Rajala, M. Raitanen Finnbladder Group Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study Eur Urol 36 1999 393 400
19. S.F. Shariat, A.Z. Weizer, and A. Green Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder Urology 56 2000 735 740
20. T.T. Wu, J.H. Chen, and Y.H. Lee The role of Bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma J Urol 163 2000 758 760
21. F. Saint, M.A. Le Frere Belda, and R. Quintela Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guerin (BCG) Eur Urol 45 2004 475 482
22. A.R. Zlotta, J.C. Noel, and I. Fayt Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Gurin intravesical therapy J Urol 161 1999 792 798
23. K. Esuvaranathan, E. Chiong, and T.P. Thamboo Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha Cancer 109 2007 1097 1105
24. K. Mellon, D.E. Neal, and M.C. Robinson Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67 Br J Urol 66 1990 281 285
25. D. Fontana, M. Bellina, and L. Gubetta Monoclonal antibody Ki-67 in the study of the proliferative activity of bladder carcinoma J Urol 148 1992 1149 1151
26. A. Quintero, J. Alvarez-Kindelan, and R.J. Luque Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder J Clin Pathol 59 2006 83 88
27. T. Lebret, V. Becette, and J.M. Herve Prognostic value of MIB-1 antibody labeling index to predict response to bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer Eur Urol 37 2000 654 659
28. Z. Popov, A. Hoznek, and M. Colombel The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder Cancer 80 1997 1472 1481